Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Total Non-current Liabilities
All obligations due after more than one year.
Tenax Therapeutics, Inc.NASDAQ: TENX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $0, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 64.2K | -65.0% |
| FY2021 | 2021-12-31 | 183.59K | — |
Total Non-current Liabilities vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 total non-current liabilities of $0 is the lowest of the 7 companies compared; the peer median is $9.21M.
- Total non-current liabilities amounts to 0.0% of total assets for TENX, versus a peer median of 13.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $292.69B | +487717.0% | +47.5% | 307.8% | |
| Mar 2026 | $45M | -6.8% | -32.7% | 31.9% | |
| Jun 2026 | $11.72M | +57.6% | +29.9% | 4.9% | |
| Mar 2026 | $6.69M | -90.2% | -60.3% | 10.5% | |
| Mar 2026 | $6.51M | -79.2% | +69.2% | 16.8% | |
| Mar 2026 | $170K | +18701870187018604.0% | +339.7% | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TENX) | $9.21M | +25.4% | +38.7% | 13.7% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.